What enGenes Biotech does

enGenes Biotech GmbH is a privately held, Vienna-based CRO/CDMO founded in 2014 as a spin-off of the University of Natural Resources and Life Sciences (BOKU) Vienna. It specializes in microbial (E. coli-based) bioprocessing for the production of recombinant proteins, plasmid DNA, and bioconjugates, addressing pain points such as low soluble yields, expensive inclusion-body processes, and long development timelines in biopharma and biotech manufacturing. The company serves pharmaceutical and biotech customers (from startups to large enterprises), diagnostics companies, and industrial biotechnology segments across food, feed, cosmetics, and flavors/fragrances.

The company's competitive core is a portfolio of six proprietary technology platforms: enGenes-eXpress™ (growth-decoupled BL21 (DE3)-derived host yielding up to 5x higher soluble titers and up to 80% COGS reduction), enGenes-eXtra™ (extracellular secretion), enGenes-eXcite™ (continuous manufacturing), enGenes-eXpand™ (non-canonical amino-acid incorporation via amber-stop codon suppression), enGenes-eXcess™ (plasmid DNA, up to 3 g/L supercoiled yield), and enGenes-eXchange™ (antibiotic-free production). Complementing the platforms is a bioprocessing products catalog including the eXrase™ recombinant endonuclease (marketed at roughly a 30-fold cost reduction vs. incumbent nucleases) and Protein A-based affinity ligands.

Commercial revenue derives from two streams: project-based CRO/CDMO services (feasibility studies, strain development, upstream/downstream development, technology transfer, contract manufacturing, and analytical support) priced on a quote basis, and one-time/bioprocessing reagent sales. Distribution is direct B2B, supported by participation in industry conferences (BioProcess International, ISCT, BIO-Europe, Swiss Biotech Day, World Vaccine Congress, Bioprocessing Summit) and a 2026 partnership with NorthX Biologics that extends delivery to GMP-scale manufacturing. The company employs fewer than ten people, is privately held by three shareholders (CEO Jürgen Mairhofer 40%, co-founder Gerald Striedner 45%, CFO Peter Hacker 15%), and is supported by Austrian public funding programs including FFG, AWS, WAFF, and Go International.

Name

enGenes Biotech

Legal name

enGenes Biotech GmbH

Website

https://engenes.cc

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

enGenes Biotech is a Vienna-based CRO/CDMO operating a proprietary E. coli-based microbial expression platform portfolio to deliver recombinant protein, plasmid DNA, and bioconjugate manufacturing services and reagents to biopharma, diagnostics, and industrial biotechnology customers.

Ownership category

akta.pro rank

Product category

Microbial Bioprocessing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Process Development & Tech Transfer Services (CDMO) (HLAGABAL), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• Microbial bioprocessing services
• Recombinant protein production
• Plasmid DNA manufacturing
• Bioprocess development services
• E. coli expression platform

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CRO/CDMO Services: End-to-end bioprocessing services covering strain design, expression optimization, process development, and GMP manufacturing. Services include feasibility studies, technology transfer, strain development, upstream development (up to 200L), downstream development, contract manufacturing, and analytical support.
2. Bioprocessing Products: Sale of proprietary reagents including eXrase endonuclease and affinity ligands for protein purification. Products available in research-grade, technical-grade, and bulk formats.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

enGenes Biotech is a Contract Research and Contract Development & Manufacturing Organization (CRO/CDMO) that delivers end-to-end microbial bioprocessing services for the recombinant production of proteins, plasmid DNA, and bioconjugates. The company combines proprietary E. coli-based expression technology platforms with bioprocess development, scale-up, and contract manufacturing capabilities, and also sells bioprocessing reagents (eXrase endonuclease, Protein A-based affinity ligands) to biotech and pharma customers.

Product overview

enGenes Biotech is a CRO/CDMO offering a portfolio of proprietary technology platforms combined with comprehensive bioprocessing services. The core technology suite includes: enGenes-eXpress™ (growth-decoupled E. coli expression platform), enGenes-eXtra™ (extracellular secretion technology), enGenes-eXcite™ (continuous manufacturing), enGenes-eXpand™ (non-canonical amino acid incorporation), enGenes-eXcess™ (plasmid DNA manufacturing yielding up to 3 g/L), and enGenes-eXchange™ (antibiotic-free production). Commercial products include eXrase™ recombinant endonuclease and Protein A-based affinity ligands. Services span feasibility studies, recombinant protein production, plasmid DNA production, technology transfer, contract manufacturing, and analytical support. The company operates as a unified platform-plus-services model where customers can access individual technologies or engage for end-to-end development and manufacturing from early feasibility through GMP production.

Differentiator

Problem solved

Functional benefit

Brands

• enGenes-eXpress: Growth-decoupled expression platform for recombinant protein and plasmid DNA production in E. coli
• enGenes-eXtra
• enGenes-eXpand
• enGenes-eXcite
• enGenes-eXcess
• enGenes-eXrase
• enGenes-eXchange
• iCAP
• ECOnti

Products and services

• enGenes-eXpress™ Patented next-generation growth-decoupled E. coli expression platform that delivers up to 5x higher soluble product yields, reduces cost of goods by up to 80% versus conventional E. coli systems, and simplifies downstream processing for difficult-to-express or toxic recombinant proteins and plasmid DNA.
• enGenes-eXtra™ Extracellular secretion technology that releases recombinant proteins into the extracellular space via E. coli's periplasmic space and leaky outer membrane, enabling simplified purification and higher yields for biotech and pharma customers.
• enGenes-eXcite™ Continuous manufacturing technology for biomolecules in E. coli that enables high yields and scalability from a very small footprint, supporting cost-effective, sustainable, and continuous production of recombinant proteins.
• enGenes-eXpand™ Technology for site-specific incorporation of non-canonical amino acids (NCAAs) via amber-stop codon suppression, enabling synthesis of modified proteins with tailored properties and cost-effective bioconjugation through click-chemistry.
• enGenes-eXcess™ Robust platform for high-yield, high-quality plasmid DNA manufacturing with optimized upstream and downstream processes enabling up to 3 g/L supercoiled pDNA for gene therapy, mRNA therapies, and vaccine development.
• enGenes-eXchange™ Antibiotic resistance marker-free manufacturing platform for recombinant proteins and plasmid DNA, using modified plasmids and E. coli strains to enable safer, more environmentally friendly production versus traditional antibiotic-dependent methods.
• iCAP Platform Integrated Continuous and Automated Platform for Plasmid Production (iCAP) — a transformational project combining bioprocess intensification and digital intelligence to deliver world-first continuous automated pDNA production for cell and gene therapy, viral vectors, and mRNA vaccines.
• eXrase™ Next-generation recombinant endonuclease for DNA/RNA digestion, available in research-grade, technical-grade, and bulk formats for controlling viscosity, enhancing filtration, and increasing recovery in industrial biotech fermentation at approximately 30-fold lower cost than traditional nucleases.
• Affinity Ligands Protein A-based affinity ligands for efficient and selective purification of biotherapeutics, including wild-type Protein A, Z4 ligand with caustic stability, hexameric ligand with caustic stability, C-terminal Cysteine variants for site-specific immobilization, and a Z4 ligand with a non-canonical amino acid for click-chemistry immobilization.
• Recombinant Protein Production Services End-to-end CRO/CDMO services for recombinant protein production using proprietary E. coli-based technology platform, covering strain development, upstream and downstream development, contract manufacturing, and analytical support from technical feasibility to commercial availability for pharmaceutical and biotech customers.
• Plasmid DNA Production Services High-yield plasmid DNA production services combining molecular biology and bioprocessing expertise with optimized fermentation, purification, and quality control to deliver plasmids meeting stringent requirements for gene therapy, vaccine development, and advanced therapeutics.
• Feasibility Study Service Structured two-phase feasibility study (8–12 weeks) that assesses technology compatibility with target molecules, beginning with high-throughput microbioreactor screening and validating candidates in fed-batch mode on a 4×1L multibioreactor system.
• Technology Transfer Service Agile, flexible process development service that enables rapid optimization and efficient production for early-stage needs, with seamless transfer to large-scale partners and cGMP facilities through enGenes' CDMO ecosystem connections.

Quantifiable outcome

• Cost of goods reduced by up to 80% compared to conventional E. coli systems
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• NorthX BiologicscoreStrategic or Co-development Partner · 26 May 2026Swedish contractor NorthX Biologics and Austrian technology firm enGenes Biotech partnered to develop an integrated E.coli-based protein production platform covering strain design through GMP manufacturing. The partnership aims to address fragmentation in the production pathway by combining high-throughput screening, multi-fermenter systems, and advanced analytical support into a single aligned workflow. The firms plan to monetize the platform by offering it as a manufacturing service to biopharma customers.
• Novasign GmbHcoreTechnology or IntegrationDevelopment partner in the ECOnti project for continuous protein production. Previously collaborated on the EConti project for continuous protein production, reuniting for the iCAP project for continuous plasmid DNA production.
• Qubicon AGcoreTechnology or IntegrationDevelopment partner in the ECOnti project for continuous protein production. Previously collaborated on the EConti project for continuous protein production, reuniting for the iCAP project for continuous plasmid DNA production.
• FFG (Austrian Research Promotion Agency)minorOthersAustrian funding agency supporting research and development in biotechnology sector, listed as partner and funding agency for enGenes Biotech.
• WKO (Austrian Federal Economic Chamber)minorOthersAustrian Federal Economic Chamber membership providing industry representation and networking support.
• AWS (Austria Wirtschaftsservice)minorOthersAustrian funding agency supporting business development and innovation.
• WAFF (Wiener ArbeitnehmerInnen Förderungsfonds)minorOthersVienna employment promotion fund supporting workforce development.
• Go InternationalminorOthersAustrian export promotion program supporting internationalization of biotech companies.
• LISAviennaminorGTM or Marketing PartnerenGenes participates in Austrian Pavilion operated by LISAvienna at BIO-Europe 2025, representing the Austrian biotech community at international partnering conferences.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NorthX Biologics: Swedish microbial CDMO offering process development and GMP manufacturing for recombinant proteins and pDNA — directly comparable in modality and now enGenes' strategic partner for integrated gene-to-GMP delivery.
• Biovian: Finland-based microbial CDMO specializing in E. coli-based recombinant proteins, viral vectors, and plasmid DNA — a near-direct peer in scale, modality, and customer base.
• BioCina: Australia-based microbial CDMO offering recombinant protein, plasmid DNA, and vaccine process development and GMP manufacturing — competes for the same microbial-biologics and pDNA workloads.
• Aldevron: US-based CDMO (now part of Danaher) with a leading plasmid DNA and protein manufacturing franchise — directly comparable on the pDNA side and a meaningful competitor for gene-therapy customers.
• VGXI: Specialist CDMO focused exclusively on plasmid DNA for gene therapy and DNA vaccines — competes head-to-head for enGenes' pDNA customers in the cell-and-gene-therapy space.

Broad incumbents

• Wacker Biotech: Established microbial CDMO within Wacker Chemie offering E. coli-based process development and GMP manufacturing of recombinant proteins, vaccines, and live biotherapeutics — a much larger incumbent in the same niche.
• Lonza: Global CDMO leader with both microbial and mammalian biologics capacity — overlaps with enGenes on recombinant protein and pDNA manufacturing at the high end of the market.
• Eurofins CDMO: Large CDMO network offering microbial process development and contract manufacturing services across biologics — competes for outsourced bioprocess development work.

Others

• AGC Biologics:

Emerging players

• Cape Biologix: South African plasmid DNA manufacturer targeting gene-therapy and DNA-vaccine customers — an emerging specialist with overlapping pDNA focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/enGenesBiotech
• LinkedInlinkedin.com/company/engenes-biotech-gmbh-

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about enGenes Biotech